MAIA Biotechnology highlights efficacy data from THIO-101 Phase 2 trial

MAIA Biotechnology (MAIA) highlights efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who had failed two or more standard-of-care therapy regimens. As of June 30, 2025, Estimated median progression free survival in third-line treatment was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months. Estimated median overall survival was 17.8 months, with a 95% confidence interval lower bound of 12.5 months and a 99% CI lower bound of 10.8 months, consistent with the prior data readout. Across patients of all treatment lines, 2 patients have completed 33 cycles of therapy, highlighting ateganosine’ potential for extended dosing, which usually translates into longer patient survival. “THIO-101 continues to reveal impressive efficacy with observed progression free survival of 5.6 months, which is more than double the standard of care PFS of just 2.5 months. The data also demonstrates the durability of ateganosine treatment through extended treatment cycles, which is in line with consistent tolerability and low toxicity,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “We are seeking further validation of ateganosine’s strong efficacy in our THIO-101 Phase 2 expansion trial, which began enrolling patients in July 2025.”